Testosterone treatment and coronary artery plaque volume in older men with low testosterone

JAMA - Journal of the American Medical Association

Volumn 317, Issue 7, 2017, Pages 708-716

  Budoff, Matthew J ^a   Ellenberg, Susan S ^b   Lewis, Cora E ^c   Mohler, Emile R ^b   Wenger, Nanette K ^d   Bhasin, Shalender ^e   Barrett Connor, Elizabeth ^f   Swerdloff, Ronald S ^g   Stephens Shields, Alisa ^b   Cauley, Jane A ^h   Crandall, Jill P ⁱ   Cunningham, Glenn R ^j   Ensrud, Kristine E ^k,l   Gill, Thomas M ^m   Matsumoto, Alvin M ⁿ   Molitch, Mark E ^o   Nakanishi, Rine ^a   Nezarat, Negin ^a   Matsumoto, Suguru ^a   Hou, Xiaoling ^b   Basaria, Shehzad ^e   Diem, Susan J ^k   Wang, Christina ^g   Cifelli, Denise ^b   Snyder, Peter J ^b   more..

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c University of Alabama at Birmingham   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^l VA MEDICAL CENTER   (United States)

^m YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^o NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TESTOSTERONE; ANDROGEN; GEL;

AGATSTON SCORE; AGE; AGED; AGING; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; CORONARY ARTERY PLAQUE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; GEL; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; RISK ASSESSMENT; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; UNITED STATES; ADVERSE EFFECTS; BLOOD; BLOOD VESSEL CALCIFICATION; CHEMICALLY INDUCED; CLINICAL TRIAL; CORONARY ANGIOGRAPHY; DIAGNOSTIC IMAGING; HORMONE SUBSTITUTION; OBSERVER VARIATION; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE;

AGED; ANDROGENS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; GELS; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; OBSERVER VARIATION; SAMPLE SIZE; TESTOSTERONE; UNITED STATES; VASCULAR CALCIFICATION;

EID: 85014000311     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.21043     Document Type: Article

References (33)

1. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med. 2013;173(15):1465-1466.
2. Barrett-Connor E, Khaw KT. Endogenous sex hormones and cardiovascular disease in men: a prospective population-based study. Circulation. 1988;78(3):539-545.
3. Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation. 2007;116(23):2694-2701.
4. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL; Rancho Bernardo Study. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo Study. Diabetes Care. 2002;25(1):55-60.
5. Smith GD, Ben-Shlomo Y, Beswick A, Yarnell J, Lightman S, Elwood P. Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study. Circulation. 2005;112(3):332-340.
6. Kloner RA, Carson C III, Dobs A, Kopecky S, Mohler ER III. Testosterone and cardiovascular disease. J AmColl Cardiol. 2016;67(5):545-557.
7. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122.
8. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2010;95(2):639-650.
9. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatalmyocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805.
10. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-1836.
11. Baillargeon J, Urban RJ, Kuo YF, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014;48 (9):1138-1144.
12. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725-733.
13. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050-2058.
14. Snyder PJ, Ellenberg SS, Cunningham GR, et al. The Testosterone Trials: seven coordinated trials of testosterone treatment in elderly men. Clin Trials. 2014;11(3):362-375.
15. Abd Alamir M, Ellenberg SS, Swerdloff RS, et al. The Cardiovascular Trial of the Testosterone Trials: rationale, design, and baseline data of a clinical trial using computed tomographic imaging to assess the progression of coronary atherosclerosis. Coron Artery Dis. 2016;27(2):95-103.
16. Cauley JA, Fluharty L, Ellenberg SS, et al. Recruitment and screening for the Testosterone Trials. J Gerontol A Biol Sci Med Sci. 2015;70(9): 1105-1111.
17. Snyder PJ, Bhasin S, Cunningham GR, et al; Testosterone Trials Investigators. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624.
18. Matsumoto S, Nakanishi R, Li D, et al. Aged garlic extract reduces low attenuation plaque in coronary arteries of patients with metabolic syndrome in a prospective randomized double-blind study. J Nutr. 2016;146(2):427S-432S.
19. Papadopoulou SL, Neefjes LA, Garcia-Garcia HM, et al. Natural history of coronary atherosclerosis by multislice computed tomography. JACC Cardiovasc Imaging. 2012;5(3)(suppl):S28-S37.
20. Raff GL, Abidov A, Achenbach S, et al; Society of Cardiovascular Computed Tomography. SCCT guidelines for the interpretation and reporting of coronary computed tomographic angiography. J Cardiovasc Comput Tomogr. 2009;3(2):122-136.
21. Dalager MG, Bøttcher M, Andersen G, et al. Impact of luminal density on plaque classification by CT coronary angiography. Int J Cardiovasc Imaging. 2011;27(4):593-600.
22. Carr JJ, Nelson JC, Wong ND, et al. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology. 2005;234 (1):35-43.
23. Zeb I, Li D, Nasir K, et al. Effect of statin treatment on coronary plaque progression-a serial coronary CT angiography study. Atherosclerosis. 2013;231(2):198-204.
24. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J AmColl Cardiol. 2014;63(25, pt B):2935-2959.
25. Basaria S, Harman SM, Travison TG, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 2015;314 (6):570-581.
26. Boogers MJ, Broersen A, van Velzen JE, et al. Automated quantification of coronary plaque with computed tomography: comparison with intravascular ultrasound using a dedicated registration algorithm for fusion-based quantification. Eur Heart J. 2012;33(8):1007-1016.
27. Fischer C, Hulten E, Belur P, Smith R, Voros S, Villines TC. Coronary CT angiography versus intravascular ultrasound for estimation of coronary stenosis and atherosclerotic plaque burden: ameta-analysis. J Cardiovasc Comput Tomogr. 2013; 7(4):256-266.
28. Hamirani YS, Kadakia J, Pagali SR, et al. Assessment of progression of coronary atherosclerosis using multidetector computed tomography angiography (MDCT). Int J Cardiol. 2011;149(2):270-274.
29. Schuhbaeck A, Dey D, Otaki Y, et al. Interscan reproducibility of quantitative coronary plaque volume and composition from CT coronary angiography using an automated method. Eur Radiol. 2014;24(9):2300-2308.
30. Gaur S, Øvrehus KA, Dey D, et al. Coronary plaque quantification and fractional flow reserve by coronary computed tomography angiography identify ischaemia-causing lesions. Eur Heart J. 2016;37(15):1220-1227.
31. Miszalski-Jamka T, Klimeczek P, Banyś R, et al. The composition and extent of coronary artery plaque detected by multislice computed tomographic angiography provides incremental prognostic value in patients with suspected coronary artery disease. Int J Cardiovasc Imaging. 2012;28(3):621-631.
32. Arbab-Zadeh A, Fuster V. Themyth of the "vulnerable plaque": transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment. J Am Coll Cardiol. 2015;65(8):846-855.
33. Samady H, Eshtehardi P, McDaniel MC, et al. Coronary artery wall shear stress is associated with progression and transformation of atherosclerotic plaque and arterial remodeling in patients with coronary artery disease. Circulation. 2011;124(7): 779-788.